The contribution of biotechnology toward progress in diagnosis, management, and treatment of allergic diseases

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 12, 2014, Pages 1588-1601

  Palomares, Oscar ^a   Crameri, R ^b   Rhyner, C ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Allergy; Biotechnology; Immunotherapy; Recombinant allergens

Indexed keywords

ALLERGEN; B LYMPHOCYTE ANTIGEN; IMMUNOGLOBULIN E; RECOMBINANT ALLERGEN; T LYMPHOCYTE ANTIGEN; VACCINE;

ALLERGENICITY; ALLERGIC DISEASE; BASOPHIL ACTIVATION TEST; BIOTECHNOLOGY; CELL ASSAY; CROSS REACTION; DISEASE CONTROL; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INNATE IMMUNITY; INTRALYMPHATIC IMMUNOTHERAPY; MICROARRAY ANALYSIS; NONHUMAN; REVIEW; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; DISEASE MANAGEMENT; HYPERSENSITIVITY; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY; PROCEDURES;

BIOTECHNOLOGY; DISEASE MANAGEMENT; HUMANS; HYPERSENSITIVITY; IMMUNOLOGIC TESTS; IMMUNOTHERAPY; VACCINES;

EID: 84909606703     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12533     Document Type: Review

References (215)

1. Crameri R, Garbani M, Rhyner C, Huitema C. Fungi: the neglected allergenic sources. Allergy 2014;69:176-185.
2. Simoens S. The cost-effectiveness of immunotherapy for respiratory allergy: a review. Allergy 2012;67:1087-1105.
3. Zuberbier T, Lötvall J, Simoens S, Subramanian SV, Church MK. Economic burden of inadequate management of allergic diseases in the European Union: a GA(2)LEN review. Allergy 2014;69:1275-1279.
4. Jutel M, Angier L, Palkonen S, Ryan D, Sheikh A, Smith H et al. Improving allergy management in the primary care network - a holistic approach. Allergy 2013;68:1362-1369.
5. Ismaila AS, Sayani AP, Marin M, Su Z. Clinical, economic, and humanistic burden of asthma in Canada: a systematic review. BMC Pulm Med 2013;13:70.
6. Boyle RJ, Dickson R, Hockenhull J, Cherry MG, Elremeli M. Immunotherapy for Hymenoptera venom allergy: too expensive for European health care? Allergy 2013;68:1341-1342.
7. Ring J, Akdis C, Behrendt H, Lauener RP, Schäppi G, Akdis M et al. Davos Declaration: allergy as a global problem. Allergy 2012;67:141-143.
8. Samoliński B, Fronczak A, Kuna P, Akdis CA, Anto JM, Bialoszewski AZ et al. Prevention and control of childhood asthma and allergy in the EU from the public health point of view: polish Presidency of the European Union. Allergy 2012;67:726-731.
9. Bousquet J, Tanasescu CC, Camuzat T, Anto JM, Blasi F, Neou A et al. Impact of early diagnosis and control of chronic respiratory diseases on active and healthy ageing: a debate at the European Union Parliament. Allergy 2013;68:555-561.
10. Igea JM. The history of the idea of allergy. Allergy 2013;68:966-973.
11. Blackley CH. Experimental researches on the causes and nature of catarrhus aestivum (Hay-fever or hay-asthma). London, UK: Baillere Tindall & Cox; 1873.
12. Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1:1572-1573.
13. Hellings PW, Fokkens WJ, Akdis C, Bachert C, Cingi C, Dietz de Loos D. Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy 2013;68:1-7.
14. Bice JB, Leechawengwongs E, Montanaro A. Biologic targeted therapy in allergic asthma. Ann Allergy Asthma Immunol 2014;112:108-115.
15. Eyerich K, Novak N. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy 2013;68:974-982.
16. Sicherer SH, Sampson HA. Food allergy: epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol 2014;133:291-307.
17. Eckl-Dorna J, Niederberger V. What is the source of serum allergen-specific IgE? Curr Allergy Asthma Rep 2012;13:281-287.
18. Ishizaka K, Ishizaka T, Hornbrook MM. Physicochemical properties of reaginic antibody. V. Correlation of reaginic activity with gamma-E-globulin antibody. J Immunol 1966;97:840-853.
19. Varner AE. The increase in allergic respiratory diseases: survival of the fittest? Chest 2002;121:1308-1316.
20. Liu AH, Murphy JR. Hygiene hypothesis: fact or fiction? J Allergy Clin Immunol 2003;111:471-478.
21. Frei R, Lauener RP, Crameri R, O'Mahony L. Microbiota and dietary interactions: an update to the hygiene hypothesis? Allergy 2012;67:451-461.
22. Larenas-Linnemann D, Cox LS. European allergen extract units and potency: review of available information. Ann Allergy Asthma Immuol 2008;100:137-145.
23. Chapman MD, Pomés A, Breiteneder H, Ferreira F. Nomenclature and structural biology of allergens. J Allergy Clin Immunol 2007;119:414-420.
24. Thomas WR. The advent of recombinant allergens and allergen cloning. J Allergy Clin Immunol 2011;127:855-859.
25. Sicherer SH, Leung DY. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2013. J Allergy Clin Immunol 2014;133:324-334.
26. Aalberse JA, Meijer Y, Derksen N, van der Palen-Merkus T, Knol E, Aalberse RC. Moving from peanut extract to peanut components: towards validation of compo-nent- resolved IgE tests. Allergy 2013;68:748-756.
27. Crameri R. The crux with a reliable in vitro and in vivo diagnosis of allergy. Allergy 2013;68:693-694.
28. Valenta R, Lidholm J, Niederberger V, Hayek B, Kraft D, Grönlund H. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy 1999;29:896-904.
29. Eller E, Bindslev-Jensen C. Clinical value of component-resolved diagnostics in peanutallergic patients. Allergy 2013;68:190-194.
30. Hiller R, Laffer S, Harwanegg C, Huber M, Schmidt WM, Twardosz A et al. Micro-arrayed allergen molecules: diagnostic gate-keepers for allergy treatment. FASEB J 2002;16:414-416.
31. Lavaud F, Bonniaud P, Dalphin JC, Leroyer C, Muller D, Tannous R et al. Usefulness of omalizumab in ten patients with severe occupational asthma. Allergy 2013;68:813-815.
32. Klimek L, Pfaar O. A comparison of immunotherapy delivery methods for allergen immunotherapy. Expert Rev Clin Immunol 2013;9:465-474.
33. Valenta R, Linhart B, Swoboda I, Niederberger V. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy 2011;66:775-783.
34. First steps to genetic engineering? Nat New Biol 1971;231:257-2588.
35. Chua KY, Stewart GA, Thomas WR, Simpson RJ, Dilworth RJ, Plozza TM et al. Sequence analysis of cDNA coding for a major house dust mite allergen, Der p 1. Homology with cysteine proteases. J Exp Med 1988;167:175-182.
36. Radauer C, Nandy A, Ferreira F, Goodman RE, Larsen JN, Lidholm J et al. Update of the WHO/IUIS Allergen Nomenclature Database based on analysis of allergen sequences. Allergy 2014;69:413-419.
37. Aalberse RC, Crameri R. IgE-binding epitopes: a reappraisal. Allergy 2011;66:1261-1274.
38. Jeanson L, Kelly M, Coste A, Guerrera IC, Fritsch J, Nguyen-Khoa T et al. Oxidative stress induces unfolding protein response and inflammation in nasal polyposis. Allergy 2012;67:403-412.
39. van Ree R, Hummelshøj L, Plantinga M, Poulsen LK, Swindle E. Allergic sensitization: host-immune factors. Clin Transl Allergy 2014;4:12.
40. Nilsson OB, Binnmyr J, Zoltowska A, Saarne T, van Hage M, Grönlund H. Characterization of the dog lipocalin allergen Can f 6: the role in cross-reactivity with cat and horse. Allergy 2012;67:751-757.
41. Subbarayal B, Schiller D, Möbs C, de Jong NW, Ebner C, Reider N et al. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen. Allergy 2013;68:1377-1386.
42. Passalacqua G, Melioli G, Bonifazi F, Bonini S, Maggi E, Senna G et al. The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy. Allergy 2013;68:1029-1033.
43. Holzweber F, Svehla E, Fellner W, Dalik T, Stubler S, Hemmer W et al. Inhibition of IgE binding to cross-reactive carbohydrate determinants enhances diagnostic selectivity. Allergy 2013;68:1269-1277.
44. Bousquet J, Anto JM, Bachert C, Bousquet PJ, Colombo P, Crameri R et al. Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GA2LEN project. Allergy 2006;61:671-680.
45. Hong X, Caruso D, Kumar R, Liu R, Liu X, Wang G et al. IgE, but not IgG4, antibodies to Ara h 2 distinguish peanut allergy from asymptomatic peanut sensitization. Allergy 2012;67:1538-1546.
46. Incorvaia C, Mauro M. Can component-resolved diagnosis overturn the current knowledge on vespid allergy? Allergy 2012;67:966-967.
47. Ballmer-Weber BK, Skamstrup Hanser K, Sastre J, Andersson K, Bätscher I, Ostling J et al. Component-resolved in vitro diagnosis of carrot allergy in three different regions of Europe. Allergy 2012;67:758-766.
48. Bokanovic D, Aberer W, Hemmer W, Heinemann A, Komericki P, Scheffel J et al. Determination of sIgE to rPhl p 1 is sufficient to diagnose grass pollen allergy. Allergy 2013;68:1403-1409.
49. Klemans RJ, Knol EF, Michelsen-Huisman A, Pasmas SG, de Kruijf-Broekman W, Bruijnzeel-Kooman CA et al. Components in soy allergy diagnostics: Gly m 2S albumin has the best diagnostic value in adults. Allergy 2013;68:1396-1402.
50. Nordlund B, Konradsen JR, Kull I, Borres MP, Önell A, Hedlin G et al. IgE antibodies to animal-derived lipocalin, kallikrein and secretoglobin are markers of bronchial inflammation in severe childhood asthma. Allergy 2012;67:661-669.
51. Müller U, Schmid-Grendelmeier P, Hausmann O, Helbling A. IgE to recombinant allergens Api m 1, Ves v 1, and Ves v 5 distinguish double sensitization from crossreaction in venom allergy. Allergy 2012;67:1069-1073.
52. Monsalve RI, Vega A, Marqués L, Miranda A, Pernandez J, Soriano V et al. Component-resolved diagnosis of vespid venom-allergic individuals: phospholipases and antigen 5s are necessary to identify Vespula or Polistes sensitization. Allergy 2012;67:528-536.
53. van Rhijn BD, van Ree R, Versteeg SA, Vlieg-Boerstra BJ, Sprikkelman AB, Terreehorst I et al. Birch pollen sensitization with cross-reactivity to food allergens predominates in adults with eosinophilic esophagitis. Allergy 2013;68:1475-1481.
54. Bonini M, Marcomini L, Gramiccioni C, Tranquilli C, Melioli G, Canonica GW et al. Microarray evaluation of specific IgE to allergen components in elite athletes. Allergy 2012;67:1557-1564.
55. Simon D, Straumann A, Dahinden C, Simon HU. Frequent sensitization to Candida albicans and profilins in adult eosinophilic esophagitis. Allergy 2013;68:945-948.
56. Hofmann SC, Fischer J, Eriksson C, Bengtsson Gref O, Biedermann T, Jakob T. IgE detection to α/β/γ-gliadin and its clinical relevance in wheat-dependent exercise-induced anaphylaxis. Allergy 2012;67:1457-1460.
57. Gondro C, Lee SH, Lee HK, Porto-Neto LR. Quality control for genome-wide association studies. Methods Mol Biol 2013;1019:129-147.
58. Bruhn S, Barrenäs F, Mobini R, Andersson BA, Chavali S, Egan BS et al. Increased expression of IRF4 and ETS1 in CD4+ cells from patients with intermittent allergic rhinitis. Allergy 2012;67:33-40.
59. Li Pira G, Ivaldi F, Moretti P, Manca F. High throughput T epitope mapping and vaccine development. J Biomed Biotechnol 2010;2010:325720.
60. Vaughan K, Peters B, Larche M, Pomes A, Broide D, Sette A. Strategies to query and display allergy-derived epitope data from the immune epitope database. Int Arch Allergy Immunol 2013;160:334-345.
61. Mäde V, Els-Heindl S, Beck-Sickinger AG. Automated solid-phase peptide synthesis to obtain therapeutic peptides. Beilstein J Org Chem 2014;10:1197-1212.
62. Moldaver D, Larché M. Immunotherapy with peptides. Allergy 2011;66:784-791.
63. Rupa P, Mine Y. Oral immunotherapy with immunodominant T-cell epitope peptides alleviates allergic reactions in a Balb/c mouse model of egg allergy. Allergy 2012;67:74-82.
64. Spangfort MD, Mirza O, Ipsen H, Van Neerven RJ, Gajhede M, Larsen JN. Dominating IgE-binding epitope of Bet v 1, the major allergen of birch pollen, characterized by X-ray crystallography and site-directed mutagenesis. J Immunol 2003;171:3084-3090.
65. Hecker J, Diethers A, Schulz D, Sabri A, Plum M, Michel Y et al. An IgE epitope of Bet v 1 and fagales PR10 proteins as defined by a human monoclonal IgE. Allergy 2012;67:1530-1537.
66. Chirumbolo S. Basophil activation test (BAT) in the diagnosis of immediate hyper-sensitivity reactions to radiocontrast media. Allergy 2013;68:1627-1628.
67. Yun J, Adam J, Yerly D, Pichler WJ. Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA. Allergy 2012;67:1338-1346.
68. Wakahara K, Van VQ, Baba N, Bègin P, Rubio M, Delespesse G et al. Basophils are recruited to inflamed lungs and exacerbate memory Th2 responses in mice and humans. Allergy 2013; 68:180-189.
69. Eržen R, Košnik M, Silar M, Korošec P. Basophil response and the induction of a tolerance in venom immunotherapy: a long-term sting challenge study. Allergy 2012;67:822-830.
70. Bieber T, Cork M, Reitamo S. Atopic dermatitis: a candidate for disease-modifying strategy. Allergy 2012;67:969-975.
71. Selb R, Eckl-Dorna J, Vrtala S, Valenta R, Niederberger V. An assay that may predict the development of IgG enhancing allergen-specific IgE binding during birch immunotherapy. Allergy 2013;68:1199-1202.
72. Nabel GJ. Designing tomorrow's vaccines. N Engl J Med 2013;368:551-560.
73. Calderon MA, Rodriguez Del Rio P, Vidal C, Just J, Pfaar O, Linneberg A et al. An EAACI "European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI)": the methodology. Clin Transl Allergy 2014;4:22.
74. Braza F, Chesne J, Castagnet S, Magnan A, Brouard S. Regulatory functions of B cells in allergic diseases. Allergy 2014;69:1454-1463.
75. Faith A, Singh N, Farooque S, Dimeloe S, Richards DF, Lu H et al. T cells producing the anti-inflammatory cytokine IL-10 regulate allergen-specific Th2 responses in human airways. Allergy 2012;67:1007-1013.
76. Soyer OU, Akdis M, Ring J, Behrendt H, Crameri R, Lauener R et al. Mechanisms of peripheral tolerance to allergens. Allergy 2013;68:161-170.
77. Melo RC, Liu L, Xenakis JJ, Spencer LA. Eosinophil-derived cytokines in health and disease: unraveling novel mechanisms of selective secretion. Allergy 2013;68:274-284.
78. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 2005;60:801-807.
79. Passalacqua G, Pasquali M, Ariano R, Lombardi C, Giardini A, Baiardini I et al. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy 2006;61:849-854.
80. Schmid-Grendelmeier P, Crameri R. Recombinant allergens for skin testing. Int Arch Allergy Immunol 2001;125:96-111.
81. Bonura A, Corinti S, Schavi E, Giacomazza D, Gianguzza F, Di Felice G et al. The major allergen of the Parietaria pollen contains an LPS-binding region with immunomodulatory activity. Allergy 2013;68:297-303.
82. Kitzmüller C, Wallner M, Deifl S, Mutschlechner S, Walterskirschen C, Zlabinger GJ et al. A hypoallergenic variant of the major birch pollen allergen shows distinct characteristics in antigen processing and T-cell activation. Allergy 2012;67:1375-1382.
83. Roulias A, Pichler U, Hauser M, Himly M, Hofer H, Lackner P et al. Differences in the intrinsic immunogenicity and allergenicity of Bet v 1 and related food allergens revealed by site-directed mutagenesis. Allergy 2014;69:208-215.
84. Baar A, Pahr S, Constantin C, Giavi S, Papadopoulos NG, Pelkonen AS et al. The high molecular weight glutenin subunit Bx7 allergen from wheat contains repetitive IgE epitopes. Allergy 2014;69:1316-1323.
85. Meyer W, Narkus A, Salapatek AM, Häfner D. Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber. Allergy 2013;68:724-731.
86. Wood RA, Sicherer SH, Burks AW, Grishin A, Henning AK, Lindblad R et al. A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy. Allergy 2013;68:803-808.
87. Pfaar O, Jung K, Wolf H, Decot E, Kleine-Tebbe J, Klimek L et al. Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio. Allergy 2012;67:630-637.
88. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001;56:498-505.
89. Vasilakos JP, Tomai MA. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants. Expert Rev Vaccines 2013;12:809-819.
90. Moussu H, Van Overtvelt L, Horiot S, Tourdot S, Airouche S, Zuercher A et al. Bifidobacterium bifidum NCC 453 promotes tolerance induction in murine models of sublingual immunotherapy. Int Arch Allergy Immunol 2012;158:35-42.
91. Melamed S, Wyatt LS, Kastenmayer RJ, Moss B. Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants. Vaccine 2013;31:4569-4577.
92. Bohnen C, Wangorsch A, Schulke S, Nakajima-Adachi H, Hachimura S, Burggraf M et al. Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice. Allergy 2013;68:1021-1028.
93. Klimek L, Bachmann MF, Senti G, Kundig TM. Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs. Expert Rev Clin Immunol 2014;10:1059-1067.
94. Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 2012;31:58-83.
95. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010;10:787-796.
96. Senti G, Johansen P, Haug S, Bull C, Gottschaller C, Muller P et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 2009;39:562-570.
97. Van Hage M, Pauli G. New vaccines for Mammalian allergy using molecular approaches. Front Immunol 2014;5:81.
98. Crameri R. Allergy vaccines: dreams and reality. Expert Rev Vaccines 2007;6:991-999.
99. Crameri R, Kündig TM, Akdis CA. Modular antigen-translocation as a novel vaccine strategy for allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 2009;9:568-573.
100. Kussebi F, Karamloo F, Rhyner C, Schmid-Grendelmeier P, Salagianni M, Mannhart C et al. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J Allergy Clin Immunol 2005;115:323-329.
101. Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 2012;129:1290-1296.
102. Ruëff F, Biló MB, Cichocka-Jarosz E, Müller U, Oude Elberink H, Sturm G. Immunotherapy for hymenoptera venom allergy: too expensive for European health care? Allergy 2013;68:407-408.
103. Aasbjerg K, Torp-Pedersen C, Backer V. Specific immunotherapy can greatly reduce the need for systemic steroids in allergic rhinitis. Allergy 2012;67:1423-1429.
104. Durham SR, Nelson HS, Nolte H, Bernstein DI, Creticos PS, Li Z et al. Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure. Allergy 2014;69:617-623.
105. Savi E, Peveri S, Senna G, Passalacqua G. Causes of SLIT discontinuation and strategies to improve the adherence: a pragmatic approach. Allergy 2013;68:1193-1195.
106. Calderon MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012;67:302-311.
107. Senti G, Johansen P, Kundig TM. Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol 2009;9:537-543.
108. Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy 1986;16:483-491.
109. Allam JP, Novak N. Immunological mechanisms of sublingual immunotherapy. Curr Opin Allergy Clin Immunol 2014;14:564-569.
110. Stelmach I, Kaluzińska-Parzyszek I, Jerzynska J, Stelmach P, Stelmach W, Majak P. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children. Allergy 2012;67:312-320.
111. Klimek L, Uhlig J, Mösges R, Rettig K, Pfaar O. A highly polymerized grass pollen extract is efficacious and safe in a randomized DBPC study using a novel up-dosing protocol. Allergy 2014;69:1629-1638.
112. Pfaar O, Demoly P, Gerth van Wijk R, Bonini S, Bousquet J, Canonica GW et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy 2014;69:854-867.
113. Sieber J, De Geest S, Shah-Hosseini K, Mosges R. Medication persistence with long-term, specific grass pollen immunotherapy measured by prescription renewal rates. Curr Med Res Opin 2011;27:855-861.
114. Mascarell L, Lombardi V, Louise A, Saint-Lu N, Chabre H, Moussu H et al. Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells. J Allergy Clin Immunol 2008;122 :603-609.
115. Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E et al. Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy 2001;31:54-60.
116. Mangan CE, Jeglum KA, Sedlacek TV, Wheeler JE, Mikuta JJ. Intralymphatic injection of BCG into rhesus monkeys. J Natl Cancer Inst 1975;55:699-704.
117. Maloy KJ, Erdmann I, Basch V, Sierro S, Kramps TA, Zinkernagel RM et al. Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci USA 2001;98:3299-3303.
118. Johansen P, Haffner AC, Koch F, Zepter K, Erdmann I, Maloy K et al. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J Immunol 2005;35:568-764.
119. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004;199:815-824.
120. Crameri R, Fluckiger S, Daigle I, Kundig T, Rhyner C. Design, engineering and in vitro evaluation of MHC class-II targeting allergy vaccines. Allergy 2007;62:197-206.
121. Wollenberg A, Feichtner K. Atopic dermatitis and skin allergies - update and outlook. Allergy 2013;68:1509-1519.
122. Pfaar O, Biedermann T, Klimek L, Sager A, Robinson DS. Depigmented-polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients. Allergy 2013;68:1306-1312.
123. Howarth P, Malling HJ, Molimard M, Devillier P. Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients. Allergy 2012;67:321-327.
124. von Gunten S, Cortinas-Elizondo F, Kollarik M, Beisswenger C, Lepper PM. Mechanisms and potential therapeutic targets in allergic inflammation: recent insights. Allergy 2013;68:1487-1498.
125. Salvilla SA, Dubois AE, Flokstra-de Block BM, Panesar SS, Worth A, Patel S et al. Disease-specific health-related quality of life instruments for IgE-mediated food allergy. Allergy 2014;69:834-844.
126. Ried JS, Baurecht H, Stuckler F, Krumsiek J, Gieger C, Heinrich J et al. Integrative genetic and metabolite profiling analysis suggests altered phosphatidylcholine metabolism in asthma. Allergy 2013;68:629-636.
127. Van den Berge M, ten Hacken NH, van der Weil E, Postma DS. Treatment of the bronchial tree from beginning to end: targeting small airway inflammation in Asthma. Allergy 2013;68:16-26.
128. Rebane A, Zimmermann M, Aab A, Ruckert B, Baurecht H, Weidinger S et al. From miRNA and mRNA expression profiling to function of keratinocytes in atopic dermatitis. Allergy 2012;67:57.
129. Leonardi A, Palmigiano A, Mazzola EA, Messina A, Milazzo EMS, Bortolotti M et al. Identification of human tear fluid biomarkers in vernal keratoconjunctivitis using iTRAQ quantitative proteomics. Allergy 2014;69:254-260.
130. Wölbing F, Biedermann T. Anaphylaxis: opportunities of stratified medicine for diagnosis and risk assessment. Allergy 2013;68:1499-1508.
131. Gevaert P, Nouri-Aria KT, Wu H, Harper CE, Takhar P, Fear DJ et al. Local receptor revision and class switching to IgE in chronic rhinosinusitis with nasal polyps. Allergy 2013;68:55-63.
132. Sackesen C, van de Veen W, Akdis M, Soyer O, Zumkehr J, Ruckert B et al. Suppression of B-cell activation and IgE, IgA, IgG1 and IgG4 production by mammalian telomeric oligonucleotides. Allergy 2013;68:593-603.
133. Barnes PJ, Casale TB, Dahl R, Pavord ID, Wechsler ME. The Asthma Control Questionnaire as a clinical trial endpoint: past experience and recommendations for future use. Allergy 2014;69:1119-1140.
134. Palomares O, Yaman G, Azkur AK, Akkoc T, Akdis M, Akdis CA. Role of Treg in immune regulation of allergic diseases. Eur J Immunol 2010;40:1232-1240.
135. Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008;205:2887-2898.
136. Niebuhr M, Baumert K, Heratizadeh A, Satzger I, Werfel T. Impaired NLRP3 inflammasome expression and function in atopic dermatitis due to Th2 milieu. Allergy 2014;69:1058-1067.
137. Gilles S, Steiert S, Zissler U, Chaker A, Bier H, Hochrein H et al. Inhibition of the airway epithelial antiviral response by pollen-derived non-allergenic substances. Allergy 2013;68:55.
138. Dittlein D, Gilles S, Hiller J, Schmidt-Weber C, Durner J, Behrendt H et al. Exposure to pollen substances activates the inflammasome machinery in human keratinocytes. Allergy 2013;68:47-48.
139. Hammad H, Lambrecht BN. Dendritic cells and airway epithelial cells at the interface between innate and adaptive immune responses. Allergy 2011;66:579-587.
140. Farrell E, O'Connor TM, Duong M, Watson RM, Strinich T, Gauvreau GM et al. Circulating myeloid and plasmacytoid dendritic cells after allergen inhalation in asthmatic subjects. Allergy 2007;62:1139-1145.
141. Faith A, Singh N, Chevretton E, Roberts D, Lee T, Corrigan C et al. Counter regulation of the high affinity IgE receptor, Fc epsilon RI, on human airway dendritic cells by IL-4 and IL-10. Allergy 2009;64:1602-1607.
142. Dua B, Smith S, Kinoshita T, Imaoka H, Gauvreau G, O'Byrne P. Myeloid dendritic cells type 2 in allergic asthma. Allergy 2013;68:1322-1326.
143. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000;192:1213-1222.
144. Rissoan M-C, Soumelis V, Kadowaki N, Grouard G, Briere F, De Waal Malefyt R et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999;283:1183-1186.
145. Zheng J, Jiang H, Li J, Tang H, Zhang X, Wang X et al. MicroRNA-23b promotes tolerogenic properties of dendritic cells in vitro through inhibiting Notch1/NF-kappa B1 signalling pathways. Allergy 2012;67:362-370.
146. Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol 2013;14:307-308.
147. Huang H, Dawicki W, Lu M, Nayyar A, Zhang X, Dordon JR. Regulatory dendritic cell expression of MHCII and IL-10 are jointly requisite for induction of tolerance in a murine model of OVA-asthma. Allergy 2013;68:1126-1135.
148. Pilette C, Jacobson MR, Ratajczak C, Detry B, Banfield G, VanSnick J et al. Aberrant dendritic cell function conditions Th2-cell polarization in allergic rhinitis. Allergy 2013;68:312-321.
149. Berin MC, Mayer L. Can we produce true tolerance in patients with food allergy? J Allergy Clin Immunol 2013;131:14-22.
150. Liu YJ. Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell-mediated allergic inflammation. J Allergy Clin Immunol 2007;120:238-244.
151. Froidure A, Shen C, Gras D, Van Snick J, Chanez P, Pilette C. Myeloid dendritic cells are primed in allergic asthma for thymic stromal lymphopoietin-mediated induction of Th2 and Th9 responses. Allergy 2014;69:1068-1076.
152. Post S, Nawijn MC, Jonker MR, Kliphuis N, van den Berge M, van Oosterhout AJM et al. House dust mite-induced calcium signaling instigates epithelial barrier dysfunction and CCL20 production. Allergy 2013;68:1117-1125.
153. Pace E, Scafidi V, Di Bona D, Siena L, Chiappara G, Ferraro M et al. Increased expression of IL-19 in the epithelium of patients with chronic rhinosinusitis and nasal polyps. Allergy 2012;67:878-886.
154. Mjosberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM, Piet B et al. Human IL-25-and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011;12:1055-1062.
155. Froidure A, Shen C, Pilette C. Up-regulation of thymic stromal lymphopoietin receptor on myeloid dendritic cells from atopic asthmatics. Allergy 2013;68:77.
156. Ohno T, Morita H, Arae K, Matsumoto K, Nakae S. Interleukin-33 in allergy. Allergy 2012;67:1203-1214.
157. Martinez FD, Vercelli D. Asthma. Lancet 2013;382:1360-1372.
158. Valenta R, Twaroch T, Swoboda I. Com-ponent- resolved diagnosis to optimize allergen-specific immunotherapy in the Mediterranean area. J Investig Allergol Clin Immunol 2007;17(Suppl 1):36-40.
159. Rodriguez R, Villalba M, Batanero E, Palomares O, Quiralte J, Salamanca G et al. Olive pollen recombinant allergens: value in diagnosis and immunotherapy. J Investig Allergol Clin Immunol 2007;17(Suppl 1):4-10.
160. Palomares O, Alcantara M, Quiralte J, Villalba M, Garzon F, Rodriguez R. Airway disease and thaumatin-like protein in an olive-oil mill worker. N Engl J Med 2008;358:1306-1308.
161. Palomares O, Cuesta-Herranz J, Rodriguez R, Villalba M. A recombinant precursor of the mustard allergen Sin a 1 retains the biochemical and immunological features of the heterodimeric native protein. Int Arch Allergy Immunol 2005;137:18-26.
162. Sirvent S, Canto B, Cuesta-Herranz J, Gomez F, Blanca N, Canto G et al. Act d 12 and Act d 13: two novel, masked, relevant allergens in kiwifruit seeds. J Allergy Clin Immunol 2014;133:1765-1767.
163. Sirvent S, Canto B, Gomez F, Blanca N, Cuesta-Herranz J, Canto G et al. Detailed characterization of Act d 12 and Act d 13 from kiwi seeds: implication in IgE cross-reactivity with peanut and tree nuts. Allergy 201469:1481-1488.
164. Golebski K, Roschmann KIL, Toppila-Salmi S, Hammad H, Lambrecht BN, Renkonen R et al. The multi-faceted role of allergen exposure to the local airway mucosa. Allergy 2013;68:152-160.
165. Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol 2014;14:141-153.
166. Perry M, Whyte A. Immunology of the tonsils. Immunol Today 1998;19:414-421.
167. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol 2009;9:679-691.
168. Price D, Ackland L, Suphioglu C. Nuts 'n' guts: transport of food allergens across the intestinal epithelium. Asia Pac Allergy 2013;3:257-265.
169. Wan H, Winton HL, Soeller C, Gruenert DC, Thompson PJ, Cannell MB et al. Quantitative structural and biochemical analyses of tight junction dynamics following exposure of epithelial cells to house dust mite allergen Der p 1. Clinl Exp Allergy 2000;30:685-698.
170. Vinhas R, Cortes L, Cardoso I, Mendes VM, Manadas B, Todo-Bom A et al. Pollen proteases compromise the airway epithelial barrier through degradation of transmembrane adhesion proteins and lung bioactive peptides. Allergy 2011;66:1088-1098.
171. Cavic M, Grozdanovic M, Bajic A, Srdic-Rajic T, Andjus PR, Gavrovic-Jankulovic M. Actinidin, a protease from kiwifruit, induces changes in morphology and adhesion of T84 intestinal epithelial cells. Phytochemistry 2012;77:46-52.
172. Zhao Y, Qin GX, Han R, Wang J, Zhang XD, Liu DD. beta-Conglycinin Reduces the Tight Junction Occludin and ZO-1 Expression in IPEC-J2. Int J Mol Sci 2014;15:1915-1926.
173. Leino MS, Loxham M, Blume C, Swindle EJ, Jayasekera NP, Dennison PW et al. Barrier disrupting effects of alternaria alternata extract on bronchial epithelium from asthmatic donors. PLoS One 2013;8:e71278.
174. Jeon SK, Kim HJ, Youm JK, Ahn SK, Choi EH, Sohn MH et al. Mite and cockroach allergens activate protease-activated receptor 2 and delay epidermal permeability barrier recovery. J Invest Dermatol 2008;128:1930-1939.
175. Trompette A, Divanovic S, Visintin A, Blanchard C, Hegde RS, Madan R et al. Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature 2009;457:585-588.
176. Renkonen J, Mattila P, Lehti S, Makinen J, Sormunen R, Tervo T et al. Birch pollen allergen Bet v 1 binds to and is transported through conjunctival epithelium in allergic patients. Allergy 2009;64:868-875.
177. Sewekow E, Bimczok D, Kahne T, Faber-Zuschratter H, Kessler LC, Seidel-Morgenstern A et al. The major soyabean allergen P34 resists proteolysis in vitro and is transported through intestinal epithelial cells by a caveolae-mediated mechanism. Br J Nutr 2012;108:1603-1611.
178. Tordesillas L, Gomez-Casado C, Garrido-Arandia M, Murua-Garcia A, Palacin A, Varela J et al. Transport of Pru p 3 across gastrointestinal epithelium - an essential step towards the induction of food allergy? Clin Exp Allergy 2013;43:1374-1383.
179. Devanaboyina SC, Cornelius C, Lupinek C, Fauland K, Dell'Antonia F, Nandy A et al. High resolution crystal structure and IgE recognition of the major grass pollen allergen Phlp 3. Allergy 2014; 69:1617-1628.
180. Corazza N, Kaufmann T. Novel insights into mechanisms of food allergy and allergic airway inflammation using experimental mouse models. Allergy 2012;67:1483-1490.
181. Calderon M, Cardona V, Demoly P, Expe EYI. One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions. Allergy 2012;67:462-476.
182. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol 2014;133:621-631.
183. Celesnik N, Vesel T, Rijavec M, Silar M, Erzen R, Kosnik M et al. Short-term venom immunotherapy induces desensitization of Fc epsilon RI-mediated basophil response. Allergy 2012;67:1594-1600.
184. Uemösi C, Zabel F, Manolova V, Bauer M, Beerli RR, Senti G et al. IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization. Allergy 2014;69:338-347.
185. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007;120:707-713.
186. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004;172:3252-3259.
187. Palomares O, Ruckert B, Jartti T, Kucuksezer UC, Puhakka T, Gomez E et al. Induction and maintenance of allergen-specific FOXP3+ Treg cells in human tonsils as potential first-line organs of oral tolerance. J Allergy Clin Immunol 2012;129:510-520.
188. Kucuksezer UC, Palomares O, Ruckert B, Jartti T, Puhakka T, Nandy A et al. Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen-specific T-cell tolerance in human tonsils and peripheral blood. J Allergy Clin Immunol 2013;131:875-885.
189. Jartti T, Palomares O, Waris M, Tastan O, Nieminen R, Puhakka T et al. Distinct regulation of tonsillar immune response in virus infection. Allergy 2014;69:658-667.
190. Kuo CH, Hsieh CC, Kuo HF, Huang MY, Yang SN, Chen LC et al. Phthalates suppress type I interferon in human plasmacytoid dendritic cells vial epigenetic regulation. Allergy 2013;68:870-879.
191. Michel S, Busato F, Genuneit J, Pekkanen J, Dalphin JC, Riedler J et al. Farm exposure and time trends in early childhood may influence DNA methylation in genes related to asthma and allergy. Allergy 2013;68:355-364.
192. Syed A, Garcia MA, Lyu SC, Bucayu R, Kohli A, Ishida S et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol 2014;133:500-510.
193. van de Veen W, Stanic B, Yaman G, Wawrzyniak M, Sollner S, Akdis DG et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol 2013;131:1204-1212.
194. Liu ZQ, Wu Y, Song JP, Liu X, Liu Z, Zheng PY et al. Tolerogenic CX3CR1(+) B cells suppress food allergy-induced intestinal inflammation in mice. Allergy 2013;68:1241-1248.
195. Kupszyk M, Dahlén B, Sterk PJ, Nizankowska-Mogilnicka E, Papi A, Bel EH et al. Stability phenotypes defined by physiological variables and biomarkers in adults with asthma. Allergy 2014;69:1198-1204.
196. Sharma V, Michel S, Gaetner V, Franke A, Vogelberg C, van Berg A et al. A role of FCER1A and FCER2 polymorphisms in IgE regulation. Allergy 2014;69:231-236.
197. Holm T, Rutishauser D, Kai-Larsen Y, Lyutvinsky Y, Stenius F, Zubrav RA et al. Protein biomarkers in vernix with potential to predict the development of atopic eczema in early childhood. Allergy 2014;69:104-112.
198. Biethahn K, Orinska Z, Vigorito E, Goyeneche-Patino DM, Mighomizadeh F, Föger N et al. miRNA-155 controls mast cell activation by regulating the PI3Ky pathway and anaphylaxis in a mouse model. Allergy 2014;69:752-762.
199. Zheng J, Jiang HY, Li J, Tang HC, Zhang XM, Wang XR et al. MicroRNA-23b promotes tolerogenic properties of dendritic cells in vitro through inhibiting Notch1/NF-kB signalling pathways. Allergy 2012;67:362-370.
200. Hawro T, Saluja R, Weller K, Altrichter S, Metz M, Maurer M. Interleukin-31 does not induce immediate itch in atopic dermatitis patients and in healthy controls after skin challenge. Allergy 2014;69:113-117.
201. Smolinska S, Jutel M, Crameri R, O'Mahony L. Histamine and gut mucosal immune regulation. Allergy 2014;69:273-281.
202. Singer J, Jensen-Jarmolin E. IgE-based immunotherapy of cancer: challenges and chances. Allergy 2014;69:137-149.
203. Ring J, Akdis C, Lauener R, Schäppi G, Traidl-Hoffmann C, Akdis M et al. Global Allergy Forum and Second Davos Declaration 2013 Allergy: barriers to cure - challenges and actions to be taken. Allergy 2014;69:978-982.
204. Agache I, Ryan D, Rodriguez MR, Yusuf O, Angier E, Jutel M. Allergy management in primary care across European countries - actual status. Allergy 2013;68:836-843.
205. De Silva D, Geromi M, Halken S, Host A, Panesar SS, Muraro A et al. Primary prevention of food allergy in children and adults: systemic review. Allergy 2014;69:581-589.
206. Muraro A, Halken S, Arshad SH, Beyer K, Dubois AE, Du Toit G et al. EAACI food allergy and anaphylaxis guidelines. Primary prevention of food allergy. Allergy 2014;69:590-601.
207. Muraro A, Roberts G, Worm M, Bilò MB, Brockow K, Fernàndez Rivas M et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy 2014;69:1026-1045.
208. Zuberbier T, Aberer W, Asero R, Bindslev-Jansen C, Brzoza Z, Canonica GW et al. Methods report on the development of the 2013 revision and update of the EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2014;69:e1-e29.
209. Papadopoulos NG, Arakawa H, Carlsen KH, Custovic A, Gem J, Lemanske R et al. International consensus on (ICON) pediatric asthma. Allergy 2012;67:976-997.
210. Scherer K, Brockow K, Aberer W, Gooi JH, Demoly P, Romano A et al. Desensitization in delayed drug hypersensitivity reactions - an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013; 68:844-852.
211. Calderón MA, Casale T, Cok L, Akdis CA, Burks AW, Nelson HS et al. Allergen immunotherapy: a new semantic framework from the European Academy of Allergy and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL consensus report. Allergy 2013;68:825-828.
212. Roberts G, Xatzipsalti M, Borrego LM, Custovic A, Halken S, Hellings PW et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy 2013;68:1102-1116.
213. Moser M, Crameri R, Menz G, Schneider T, Dudler T, Virchow C et al. Cloning and expression of recombinant Aspergillus fumigatus allergen I/a (rAsp f I/a) with IgE binding and type I skin test activity. J Immunol 1992;149:454-460.
214. Crameri R, Lidholm J, Grönlund H, Stüber D, Blaser K, Menz G. Automated specific IgE assay with recombinant allergens: evaluation of the recombinant Aspergillus fumigatus allergen I in the Pharmacia Cap system. Clin Exp Allergy 1996;26:1411-1419.
215. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P et al. Vaccination with genetically engineered allergens prevents progression of allergic diseases. Proc Natl Acad Sci USA 2004;101:14677-14682.